Edition:
India

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

94.25EUR
18 Sep 2018
Change (% chg)

€-2.45 (-2.53%)
Prev Close
€96.70
Open
€96.70
Day's High
€96.70
Day's Low
€92.55
Volume
182,637
Avg. Vol
131,586
52-wk High
€124.90
52-wk Low
€67.11

Latest Key Developments (Source: Significant Developments)

I-Mab Biopharma, Morphosys Announce China IND Submission Of TJ202/MOR202
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - MorphoSys AG ::I-MAB BIOPHARMA AND MORPHOSYS ANNOUNCE CHINA IND SUBMISSION OF TJ202/MOR202.MORPHOSYS AG- I-MAB HAS SUBMITTED AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO CHINA NATIONAL DRUG ADMINISTRATION (CNDA) FOR TJ202/MOR202.  Full Article

Germany's Morphosys Has Lower Q2 Sales, Greater Oper. Loss
Thursday, 2 Aug 2018 

Aug 1 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS AG REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE 8.1 MILLION EUR VERSUS 11.7 MILLION EUR YEAR AGO.MORPHOSYS IS INCREASING ITS FINANCIAL GUIDANCE FOR 2018, EXPECTING REVENUES OF BETWEEN EUR 67 AND 72 MILLION, EBIT OF EUR -55 TO -65 MILLION.MORPHOSYS- CO AND GALAPAGOS ENTERED INTO GLOBAL LICENSE AGREEMENT WITH NOVARTIS FOR MOR106; CO AND GALAPAGOS TO JOINTLY RECEIVE UP-FRONT PAYMENT OF EUR 95 MILLION.CASH POSITION INCREASED TO EUR 450.5 MILLION AS OF JUNE 30, 2018.EARNINGS BEFORE INTEREST AND TAXES (EBIT) IN Q2 2018 AMOUNTED TO EUR -24.1 MILLION (Q2 2017: EUR -15.4 MILLION).2018 EXPENSES FOR PROPRIETARY DEVELOPMENT AND TECHNOLOGY DEVELOPMENT ARE EXPECTED TO BE IN A CORRIDOR OF EUR 87 TO 97 MILLION.  Full Article

Morphosys And Galapagos Sign Global License Agreement For Mor106 With Pharma Partner
Thursday, 19 Jul 2018 

July 19 (Reuters) - GALAPAGOS NV ::REG-MORPHOSYS AND GALAPAGOS SIGN GLOBAL LICENSE AGREEMENT FOR MOR106 WITH TOP PHARMA PARTNER.EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH NOVARTIS ON MOR106.UP-FRONT PAYMENT OF EUR 95 MILLION (USD 111 MILLION*) AND POTENTIAL MILESTONE PAYMENTS OF UP TO APPROXIMATELY EUR 850 MILLION (USD 1 BILLION*).NOVARTIS TO BEAR ALL FUTURE RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION COSTS.AGREEMENT BETWEEN MORPHOSYS, GALAPAGOS, AND NOVARTIS IS SUBJECT TO CLEARANCE BY US ANTITRUST AUTHORITIES UNDER HART-SCOTT-RODINO ACT.ROYALTIES UP TO LOW-TEENS TO LOW-TWENTIES.  Full Article

Annual General Meeting Of Morphosys AG Elects New Supervisory Board Members
Friday, 18 May 2018 

May 17 (Reuters) - MorphoSys AG ::DGAP-NEWS: ANNUAL GENERAL MEETING OF MORPHOSYS AG ELECTS NEW SUPERVISORY BOARD MEMBERS.SHAREHOLDERS APPROVED ALL RESOLUTIONS PROPOSED BY COMPANY'S MANAGEMENT AT ITS ANNUAL GENERAL MEETING ON THURSDAY.PROPOSAL APPROVED INCLUDE APPOINTMENT OF PRICEWATERHOUSECOOPERS AG AS AUDITOR FOR 2018 FINANCIAL YEAR.  Full Article

Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million
Tuesday, 24 Apr 2018 

April 23 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS ANNOUNCES CLOSING OF NASDAQ IPO THROUGH AN ADS OFFERING AND EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS, LEADING TO TOTAL GROSS PROCEEDS OF USD 239 MILLION.SAYS EXPECTS GROSS PROCEEDS OF TRANSACTION TO AMOUNT TO USD 239,006,800.  Full Article

Morphosys ADS Debut At $26.16, Slightly Above IPO Price
Thursday, 19 Apr 2018 

April 19 (Reuters) - MorphoSys AG ::MORPHOSYS AG ADS DEBUT AT $26.16 ON THE NASDAQ VERSUS IPO PRICE OF $25.04/ADS.  Full Article

Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq
Thursday, 19 Apr 2018 

April 18 (Reuters) - MorphoSys AG ::MORPHOSYS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS) ON NASDAQ.OFFERING PRODUCED GROSS PROCEEDS OF $207.8 MILLION FROM SALE OF 2.07 MILLION NEW ORDINARY SHARES IN FORM OF 8.3 MILLION ADS AT $25.04 PER ADS.  Full Article

Morphosys to increase capital to implement Offering Of 8.3 mln ADS
Wednesday, 18 Apr 2018 

April 17 (Reuters) - MorphoSys AG ::DGAP-ADHOC: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE OFFERING OF 8,300,000 AMERICAN DEPOSITARY SHARES (ADS) IN THE UNITED STATES.TO INCREASE SHARE CAPITAL OF MORPHOSYS AG BY ISSUING 2.1 MILLION NEW SHARES, EXCLUDING PRE-EMPTIVE RIGHTS OF EXISTING SHAREHOLDERS.TO IMPLEMENT IPO IN UNITED STATES OF 8.3 MILLION AMERICAN DEPOSITARY SHARES PURSUANT TO A REGISTRATION STATEMENT ON FORM F-1.PRICING OF OFFERING IS EXPECTED TO OCCUR ON APRIL 18, 2018, FOLLOWING END OF BOOKBUILDING IN UNITED STATES.  Full Article

Morphosys Says Licensee Janssen Receives Approval For Tremfya In Canada
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - MORPHOSYS AG ::DGAP-NEWS: MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED APPROVAL FOR TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA.MORPHOSYS IS ELIGIBLE TO RECEIVE ROYALTIES ON NET SALES OF TREMFYA.  Full Article

Morphosys Increases Financial Guidance For 2017
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - MORPHOSYS AG ::INCREASES FINANCIAL GUIDANCE FOR 2017 FOLLOWING SIGNATURE OF REGIONAL LICENSE AGREEMENT FOR ANTIBODY MOR202 WITH I-MAB.‍FOR YEAR 2017, MORPHOSYS NOW EXPECTS REVENUES IN RANGE FROM EUR 63 TO 66 MILLION​.NOW EXPECTS FY EBIT OF EUR -66 TO -71 MILLION (UP FROM PREVIOUSLY EUR -75 TO -85 MILLION).FY ‍PROPRIETARY RESEARCH AND DEVELOPMENT EXPENSES WILL BE IN RANGE FROM EUR 96 TO 100 MILLION (PREVIOUSLY EUR 85 TO 95 MILLION)​.RECEIVES AN IMMEDIATE UPFRONT PAYMENT OF USD 20 MILLION FROM LICENSE AGREEMENT SIGNED.WILL BE ENTITLED TO RECEIVE ADDITIONAL MILESTONE PAYMENTS FROM I-MAB OF UP TO C. USD 100 MILLION.TO BE ENTITLED TO RECEIVE TIERED, DOUBLE-DIGIT ROYALTIES ON NET SALES OF MOR202 IN TERRITORY.SHARES JUMP 5.2 PERCENT​.  Full Article

German stocks - Factors to watch on September 13

BERLIN, Sept 13 The following are some of the factors that may move German stocks on Thursday: